Credits: 0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.56 AANP, including 0.56 AANP Pharm  

Overview: In this podcast expert faculty will review the available options and discuss best practices for prescribing and monitoring long-term anti-obesity medications (AOM) as an important component of a chronic disease approach to obesity management. The discussion will include the indications, efficacy, safety, and adverse effects of currently FDA-approved AOM as well as the evidence supporting new agents like the GLP-1 receptor agonists and the newly approved dual GIP/GLP-1 receptor agonist tirzepatide.